Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Change in Account Payables (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Change in Account Payables for 9 consecutive years, with -$1.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables rose 33.5% year-over-year to -$1.3 million, compared with a TTM value of -$453000.0 through Dec 2025, up 67.17%, and an annual FY2025 reading of -$453000.0, up 67.17% over the prior year.
  • Change in Account Payables was -$1.3 million for Q4 2025 at Puma Biotechnology, down from $962000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $8.9 million in Q3 2021 and bottomed at -$8.9 million in Q4 2021.
  • Average Change in Account Payables over 5 years is -$351000.0, with a median of -$45000.0 recorded in 2021.
  • Peak annual rise in Change in Account Payables hit 1067.02% in 2021, while the deepest fall reached 1863.05% in 2021.
  • Year by year, Change in Account Payables stood at -$8.9 million in 2021, then increased by 4.35% to -$8.5 million in 2022, then skyrocketed by 121.54% to $1.8 million in 2023, then plummeted by 209.41% to -$2.0 million in 2024, then soared by 33.5% to -$1.3 million in 2025.
  • Business Quant data shows Change in Account Payables for PBYI at -$1.3 million in Q4 2025, $962000.0 in Q3 2025, and -$602000.0 in Q2 2025.